SAT0181 Effect of anti-il-6 therapy on serum levels of metabolic syndrome-related biomarkers in rheumatoid arthritis patients. (12th June 2018)

• Record Type: Journal Article
• Authors: Genre, F.; Remuzgo-Martínez, S.; López-Mejías, R.; Mijares, V.; Calvo-Alen, J.; Blanco, R.; Llorca, J.; Castañeda, S.; González-Gay, Á. M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 951
• Page End: 951
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6829
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Metabolic syndrome (MeS) is a pathologic state that encompasses metabolic anomalies such as hyperglycemia, dyslipidemia, obesity and hypertension and that, apart from being a cardiovascular risk factor, it has been associated with chronic inflammatory diseases such as rheumatoid arthritis (RA) 1, 2 . Ghrelin and retinol binding protein-4 (RBP-4) are two biomarkers associated with MeS, and are also linked to different cardiometabolic risk factors. In this regard, it is known that ghrelin exerts an anti-inflammatory role, while RBP-4 has a pro-inflammatory role 2 . Objectives: Since a beneficial effect on endothelial function has been reported for anti-IL-6 therapy 3, we aimed to evaluate the effect of a single infusion of anti-IL-6 on the serum levels of ghrelin and RBP-4 in patients with RA. Methods: Ghrelin and RBP-4 levels were measured in serum samples from 50 Spanish individuals with RA that fulfilled the 2010 classification criteria 4, and that were under treatment with the anti-IL-6 monoclonal antibody Tocilizumab. Patients with diabetes mellitus or plasma glucose levels >110 mg/dL were excluded. Blood samples were taken in the fasting state, immediately before (time 0) and after (time 60 minutes) Tocilizumab infusion. Results: A significant increase in serum levels of ghrelin was observed after a single infusion of Tocilizumab (mean±standard deviation: 72.99±58.43 pg/mL versus 134.02±225.93 pg/mL, before and after Tocilizumab infusion, p=0.04). Serum levels of RBP-4 were not affected by the administration of Tocilizumab (mean±standard deviation: 23.48±13.99 μg/mL versus 20.90±15.54 μg/mL, before and after Tocilizumab infusion, p=0.42). Conclusions: Our results show that ghrelin levels increase after a single infusion of Tocilizumab, supporting the hypothesis that IL-6 blockade has a rapid beneficial effect on factors associated with MeS and cardiovascular risk in RA patients. Hence, long-term treatment with anti-IL-6 may reduce the risk of developing cardiovascular disease in RA. References: [1] Best Pract Res Clin Rheumatol2016;30(5):851–869. [2] Biomed Res Int2014;2014:860651. [3] Atherosclerosis2011;219:734–36. [4] Arthritis Rheum2010;62:2569–81. Acknowledgements: FG is a recipient of a Sara Borrell post-doctoral fellowship from the Instituto de Salud Carlos III (ISCIII)(Spain), co-funded by European Social Fund (ESF, "Investing in your future") (CD15/00095). SR-M is supported by funds of the RETICS Program (RIER) RD16/0012/0009 (ISCIII, co-funded by the European Regional Development Fund, ERDF). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (CP16/00033). VM is supported by funds of a Miguel Servet type I programme (CP16/00033)(ISCIII, co-funded by ERDF). Disclosure of Interest: None declared